Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

Stock Information for Oncorus Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oncorus Inc.

Oncorus Announces Workforce Reduction Plan
Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates
Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates
Oncorus to Participate in Upcoming Investor Conferences
Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting
Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates
Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.